Skip to main content

Drug Interactions between Caprelsa and Equaline Heartburn Relief

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

raNITIdine vandetanib

Applies to: Equaline Heartburn Relief (ranitidine) and Caprelsa (vandetanib)

The use of vandetanib with proton pump inhibitors may theoretically reduce its gastrointestinal absorption. Vandetanib exhibits pH-dependent solubility, with increased solubility at lower pH. The clinical significance is unknown. In healthy subjects, no clinically significant changes in the Cmax and AUC of vandetanib occurred, after coadministration of a single dose of vandetanib with five daily doses of omeprazole, or after coadministration of a single dose of vandetanib and two doses of ranitidine 12 hours apart. Dose adjustments are not required when vandetanib is administered with omeprazole or ranitidine.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid" (2007):
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. "Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals (2011):
View all 4 references

Switch to consumer interaction data

Drug and food interactions

Minor

raNITIdine food

Applies to: Equaline Heartburn Relief (ranitidine)

H2 antagonists may reduce the clearance of nicotine. Cimetidine, 600 mg given twice a day for two days, reduced clearance of an intravenous nicotine dose by 30%. Ranitidine, 300 mg given twice a day for two days, reduced clearance by 10%. The clinical significance of this interaction is not known. Patients should be monitored for increased nicotine effects when using the patches or gum for smoking cessation and dosage adjustments should be made as appropriate.

References

  1. Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM "Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans." Eur J Clin Pharmacol 38 (1990): 165-9

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer